Microbiota Modulation in Antimicrobial Resistance Management

Antimicrobial resistance (AMR) has eroded the efficacy of standard therapies and created an urgent need for complementary strategies. Modulating the gut microbiota represents a promising approach to limit the emergence, persistence and transmission of resistant organisms. The healthy gut community provides colonisation resistance by occupying ecological niches, competing for nutrients and producing antimicrobial metabolites. Disruption of this balance through antibiotic use or illness leads to dysbiosis, loss of key commensals and expansion of multidrug-resistant organisms. Restoration of microbial diversity and function can be achieved by targeted dietary interventions, probiotics and, most powerfully, faecal microbiota transplantation (FMT) or next-generation live biotherapeutic products. These modalities can reduce the overall burden of resistance genes (the resistome), suppress opportunistic pathogens and lower the incidence of infections such as Clostridioides difficile and urinary tract infections. Translational studies have demonstrated that successful engraftment of donor communities correlates with long-term reduction in resistance gene abundance. By integrating insights from microbial ecology, host immunity and clinical trials, microbiota modulation is now being positioned as both a preventive and therapeutic pillar in AMR management, with global significance across hospital, community and agricultural settings.

Research from Nature Portfolio

A large cohort study in renal transplant recipients employed deep sequencing to link gut uropathogen abundance with subsequent bacteriuria and urinary tract infection risk. By profiling 510 faecal specimens and correlating relative abundances of Escherichia and Enterococcus with clinical outcomes, the research established that even low-level colonisation in the gut serves as an independent predictor of urinary tract invasion. Strain-level analyses confirmed the gut as a reservoir for pathogenic clones, underscoring the potential of microbiota-targeted decolonisation strategies to prevent infection. The findings support therapeutic modulation of the intestinal community to reduce extra-intestinal complications of AMR.

Microbiota Modulation in Antimicrobial Resistance Management publication trend

The graph below shows the total number of articles in microbiota modulation in antimicrobial resistance management across all publications each year (not limited to Nature Index journals).

Technical terms

Gut microbiota: The community of microorganisms residing in the gastrointestinal tract that contributes to host digestion, immunity and colonisation resistance.

Colonisation resistance: The ability of a healthy microbial community to prevent establishment and overgrowth of pathogenic or resistant species.

Resistome: The collection of all antibiotic resistance genes carried by microbes in a particular environment, such as the gut.

Faecal microbiota transplantation (FMT): The transfer of stool from a healthy donor into the intestinal tract of a recipient to restore microbial diversity and function.

Dysbiosis: A disruption in the normal composition or function of the microbiota, often associated with disease or increased susceptibility to infection.

References

1. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nature Communications (2019).
2. Integrating research on bacterial pathogens and commensals to fight infections—an ecological perspective. The Lancet Microbe (2024).
3. Long-term beneficial effect of faecal microbiota transplantation on colonisation of multidrug-resistant bacteria and resistome abundance in patients with recurrent Clostridioides difficile infection. Genome Medicine (2024).